Metabomed is a drug discovery company in the field of cancer metabolism. The company is developing a proprietary target identification platform based on computational biology, genomics, and metabolomics. The platform identifies metabolic pathways that arise uniquely in cancers that enable and support their growth. Metabomed focuses on targets that form synthetic lethal pairs with inactivated metabolic genes, to disrupt the inherent survival mechanisms of cancer cells and prevent cancer cells from adapting to their metabolic constraints.

Metabomed (מטאבומד בע"מ)

Metabomed (מטאבומד בע"מ)